Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine

被引:74
作者
Carr, A
Rodríguez, E
Arango, MD
Camacho, R
Osorio, M
Gabri, M
Carrillo, G
Valdés, Z
Bebelagua, Y
Pérez, R
Fernández, LE
机构
[1] Ctr Mol Immunol, Havana 11600, Cuba
[2] Natl Inst Oncol & Radiobiol, Havana, Cuba
[3] Quilmes Natl Univ, Dept Sci & Technol, Mol Oncol Lab, Buenos Aires, DF, Argentina
关键词
D O I
10.1200/JCO.2003.02.124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : A heterophilic ganglioside cancer vaccine was developed by combining NeuGcGM3 with the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). A phase I clinical trial was performed to determine safety and immunogenicity of this vaccine. Patients and Methods: Stage III to IV breast cancer patients received up to 15 (200 mug) doses of the vaccine by intramuscular injection. The first five doses (induction phase) were given at 2-week intervals, with the remaining treatment (maintenance) administered on a monthly basis. Results: Twenty-one patients, 11 of whom had metastatic disease, were included. Main toxicities included erythema and induration at the injection site, sometimes associated with mild pain, and low-grade fever (World Health Organization grades 1 and 2). All treated patients who completed the induction phase developed anti-NeuGcGM3 antibody titers between 1:1,280 and 1:164,000 immunoglobulin G (IgG), and 1:640 and 1: 164,000 IgM. Noteworthy specific IgA antibodies were induced by vaccination in all stage III patients and in three stage IV patients. Serum antibody levels were higher in the stage III patients, with the larger increases observed after week 32. The antiganglioside IgG subclasses were mainly IgG1 and IgG3. Hyperimmune sera increased complement-mediated cytotoxicity versus P3X63 myeloma cells and a marked IgG differential reactivity against human mammary ductal carcinoma samples. Conclusion: NeuGcGM3/VSSP/Montanide ISA 51 is an unusual immunogenic ganglioside vaccine and also seems to be safe in this small trial. Immunologic surrogates of activity indicate that this reagent warrants further investigation. J Clin Oncol 21:1015-1021. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:1015 / 1021
页数:7
相关论文
共 31 条
  • [1] Alonso DF, 1999, INT J ONCOL, V15, P59
  • [2] A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors
    Carr, A
    Mullet, A
    Mazorra, Z
    Vázquez, AM
    Alfonso, M
    Mesa, C
    Rengifo, E
    Pérez, R
    Fernández, LE
    [J]. HYBRIDOMA, 2000, 19 (03): : 241 - 247
  • [3] GANGLIOSIDE GD2 SPECIFIC MONOCLONAL ANTIBODY-3F8 - A PHASE-I STUDY IN PATIENTS WITH NEUROBLASTOMA AND MALIGNANT-MELANOMA
    CHEUNG, NKV
    LAZARUS, H
    MIRALDI, FD
    ABRAMOWSKY, CR
    KALLICK, S
    SAARINEN, UM
    SPITZER, T
    STRANDJORD, SE
    COCCIA, PF
    BERGER, NA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1430 - 1440
  • [4] DEVINE PL, 1991, CANCER RES, V51, P5826
  • [5] DORE JF, 1990, B CANCER, V77, P881
  • [6] Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP)
    Estevez, F
    Carr, A
    Solorzano, L
    Valiente, O
    Mesa, C
    Barroso, O
    Sierra, GV
    Fernandez, LE
    [J]. VACCINE, 1999, 18 (1-2) : 190 - 197
  • [7] FOLCH J, 1957, J BIOL CHEM, V226, P497
  • [8] FURUKAWA K, 1988, J BIOL CHEM, V263, P18507
  • [9] Godding V, 2000, Acta Otorhinolaryngol Belg, V54, P255
  • [10] HAKOMORI S, 1985, CANCER RES, V45, P2405